- Home
- GEG vs DXR Comparison
GEG vs DXR Comparison
Compare GEG & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- DXR
- Stock Information
- Founded
- GEG 1994
- DXR 1970
- Country
- GEG United States
- DXR United States
- Employees
- GEG N/A
- DXR N/A
- Industry
- GEG Computer Software: Prepackaged Software
- DXR Medical/Dental Instruments
- Sector
- GEG Technology
- DXR Health Care
- Exchange
- GEG Nasdaq
- DXR Nasdaq
- Market Cap
- GEG 52.4M
- DXR 42.6M
- IPO Year
- GEG N/A
- DXR N/A
- Fundamental
- Price
- GEG $1.84
- DXR $8.20
- Analyst Decision
- GEG
- DXR Strong Buy
- Analyst Count
- GEG 0
- DXR 1
- Target Price
- GEG N/A
- DXR $24.75
- AVG Volume (30 Days)
- GEG 55.0K
- DXR 25.8K
- Earning Date
- GEG 02-11-2025
- DXR 01-01-0001
- Dividend Yield
- GEG N/A
- DXR N/A
- EPS Growth
- GEG N/A
- DXR N/A
- EPS
- GEG N/A
- DXR 0.35
- Revenue
- GEG $18,516,000.00
- DXR $154,205.00
- Revenue This Year
- GEG N/A
- DXR N/A
- Revenue Next Year
- GEG N/A
- DXR N/A
- P/E Ratio
- GEG N/A
- DXR $23.30
- Revenue Growth
- GEG 83.09
- DXR N/A
- 52 Week Low
- GEG $1.70
- DXR $7.19
- 52 Week High
- GEG $2.12
- DXR $10.04
- Technical
- Relative Strength Index (RSI)
- GEG 53.59
- DXR 38.64
- Support Level
- GEG $1.76
- DXR $8.01
- Resistance Level
- GEG $1.88
- DXR $8.42
- Average True Range (ATR)
- GEG 0.03
- DXR 0.40
- MACD
- GEG 0.00
- DXR -0.12
- Stochastic Oscillator
- GEG 85.71
- DXR 9.55
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.